We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Todd Morgan

Todd M Morgan MD

Associate Professor of Urology, University of Michigan, Ann Arbor, MI

Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies. Dr. Morgan is originally from Seattle, WA, and completed his undergraduate and medical training at Harvard University. He returned to the Northwest in 2003 for his urology residency at the University of Washington, before moving to Nashville for his fellowship training in urological oncology at Vanderbilt University. Currently an Associate Professor of Urology, he has been at the University of Michigan since 2012. Dr. Morgan is a translational surgeon-scientist, and his research spans the spectrum from preclinical laboratory-based research to prospective clinical trials. The primary focus of his laboratory is on identifying key pathways that predict response and resistance to treatment in genitourinary malignancies. This includes work in prostate cancer to develop liquid biopsy approaches that can guide precision-based therapeutic strategies in real time, as well as ongoing research in renal cell carcinoma to identify genomic signatures for risk stratification. Dr. Morgan also directs a number of clinical trials, primarily focused on understanding how cancer biomarkers can be utilized in order to provide more individualized management approaches. His research has received funding from the National Cancer Institute (NCI), the Department of Defense, the Prostate Cancer Foundation, the Alfredd A. Taubman Medical Research Institute, and the National Comprehensive Cancer Network, among others.

Disclosures

Dr. Morgan reports no disclosures.

Recent Contributions to PracticeUpdate:

  1. Quality Indicators in the Management of Bladder Cancer